课题基金 / 基金详情

项目摘要

项目成果

Jian-Xing Ma的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者的研究机构。 糖尿病是一种流行病在美国和世界。俄克拉荷马州是糖尿病患病率最高的州之一。据估计,俄克拉荷马州约有10%的人口患有糖尿病,在我们的一些美洲原住民社区中,患病率可高达40%。因此,糖尿病是一种 这是对工作人口健康的主要威胁,也是俄克拉荷马州的社会和经济负担。2005年,俄克拉荷马州大学健康科学中心(OUHSC)将糖尿病研究确定为该大学未来五年研究战略计划的两大优先事项之一。俄克拉荷马州 2006年批准了1050万美元作为建立哈罗德哈姆俄克拉荷马州糖尿病中心的初始资金。美洲原住民对该中心的支持已经得到保证。为了进一步扩大我们目前在俄克拉荷马州的糖尿病研究计划,OUHSC建议糖尿病患者申请COBRE,其目标如下:1)指导糖尿病研究中有前途的初级研究者(PJI),并支持他们成为NIH资助的研究人员 独立调查员。本项目选择了5个PJI,每个PJI至少有一名导师。与OUHSC战略计划一起,COBRE还将招募新的初级研究人员,以扩大我们的糖尿病研究计划。2)建立研究基础设施,支持糖尿病研究,并形成 哈罗德哈姆俄克拉荷马州糖尿病中心。3)促进和加强基础科学家和临床医生之间的合作,促进转化研究,以开发糖尿病的新治疗和预防措施。这5个PJI有从基础实验室研究到干预研究的各种项目。导师团队包括具有糖尿病研究和糖尿病护理经验的知名科学家和临床医生。4)通过与部落建立伙伴关系,改善对美洲土著糖尿病的研究和干预。一些导师正在进行的项目,以研究糖尿病在美洲原住民。两个PJI项目将解决美国原住民糖尿病的遗传因素和干预措施。这个COBRE,如果得到资助,将大大加强俄克拉荷马州的糖尿病研究,并建立哈罗德哈姆俄克拉荷马州糖尿病中心的核心。该中心赠款将对俄克拉荷马州的糖尿病护理和糖尿病患者的生活质量产生重大影响,特别是在承担不成比例份额的少数民族人群中 糖尿病的流行。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Diabetes is an epidemic in the US and in the world. Oklahoma is among the states with highest diabetes prevalence. As estimated, approximately 10% of the population in Oklahoma is diabetic, and among some of our Native Americans communities, the prevalence can be as high as 40%. Thus, diabetes represents a major threat to the health of the working population and a social and economic burden in Oklahoma. In 2005, University of Oklahoma Health Sciences Center (OUHSC) identified diabetes research as one of the top two priorities for the University's Research Strategic Plan for the next five years. The state of Oklahoma approved $10.5 million in 2006 as the initial funds to establish The Harold Hamm Oklahoma Diabetes Center. Native American support for the center has been secured. To further expand our current diabetes research program in Oklahoma, OUHSC recommended diabetes to apply for a COBRE with the following goals: 1) To mentor promising junior investigators (PJI) in diabetes research and support them to become NIH funded independent investigators. This project has selected 5 PJI with at least one mentor each. Together with the OUHSC Strategic Plan, the COBRE will also recruit new junior investigators to expand our diabetes research program. 2) To establish research infrastructures to support diabetes research and form a core for the emerging Harold Hamm Oklahoma Diabetes Center. 3) To foster and enhance collaborations between basic scientists and clinicians, and facilitate translational research toward the development of new treatments and preventive measures for diabetes. The 5 PJI have diverse projects from basic bench research to intervention studies. The mentor team includes established scientists and clinicians with experience in diabetes research and diabetes care. 4) To improve research and intervention for diabetes in Native Americans by forming partnerships with the tribes. Some of mentors have ongoing projects to study diabetes in Native Americans. Two PJI projects will address genetic factors and interventions for diabetes in Native Americans. This COBRE, if funded, will greatly strengthen diabetes research in Oklahoma and establish the core for The Harold Hamm Oklahoma Diabetes Center. This center grant will have great impacts on diabetes care and the quality of life of diabetic patients in Oklahoma, especially among minority populations who bear a disproportionate share of the diabetes epidemic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dysregulation of PPARα in RPE degeneration
Sustained release of fenofibrate for the treatment of diabetic retinopathy
  • 批准号:
    10521702
  • 项目类别:
  • 资助金额:
    $55.18万
  • 财政年份:
    2022
  • 负责人:
    Jian-Xing Ma
  • 依托单位:
cGAS-STING signaling in diabetic retinopathy
Sustained release of fenofibrate for the treatment of diabetic retinopathy
  • 批准号:
    10684823
  • 项目类别:
  • 资助金额:
    $53.8万
  • 财政年份:
    2022
  • 负责人:
    Jian-Xing Ma
  • 依托单位:
海外基金